There is growing research interest in the relationship between cancer and dementia. The necessity for innovative and efficient drug discovery methods is justified by the variety of the disease and the slow pace of therapeutic advancement in neurodegenerative disease. Drug repurposing is a revolutionary strategy that renews the traditional drug development process by demonstrating novel therapeutic applications for already approved medications. The idea of repurposing anticancer medications as innovative therapies has merit because of the shared molecular foundation and inverse tuning between cancer and neurodegeneration. There are numerous studies in the literature that highlight the success of anticancer medications as repurposed therapies. Among this the nuclear retinoid X receptor agonist bexarotene has coupled the restoration of cognitive ability (AD) by enhancing apoE expression in mice models of Alzheimer's disease. Recent investigations have demonstrated that treatment with bexarotene reduces the number of soluble forms of Aβ, particularly Aβ oligomers. Since then, bexarotene has been the subject of extensive discussion and numerous follow-up studies. Bexarotene is a special substance since the US-FDA has given it approval for use in other conditions, and there is evidence to support its mode of action in Alzheimer’s disease. These results and bexarotene's emerging significance in the treatment of Alzheimer's dementia are discussed in this review. In order to create possible repurposed medications with no toxicity for neurodegenerative disorder, This review encourages more research to better understand the possible benefits of anticancer medications.